Unlearn, a developer specializing in digital replicas, recently disclosed its at...
Johnson & Johnson’s recent triumph with its $6.5 billion autoimmune medication i...
The recent buzz surrounding a potential bidding war for the cancer specialist Mo...
A Chinese biotechnology company’s experimental gene therapy has demonstrated enc...
In an unforeseen development, the FDA’s directive for a labeling alteration conc...
Novo Nordisk has announced its highest annual profit in decades, attributing it ...
Defender Pharmaceuticals, headquartered in St. Louis, faces a setback in its que...
It appears that Sarepta Therapeutics’ upcoming treatment for Duchenne muscular d...
A non-opioid pain reliever has demonstrated efficacy in two extensive clinical t...
Novo Nordisk has signed a partnership with EraCal Therapeutics, a Swiss biotech ...
Gilead encountered a significant setback concerning its antibody-drug conjugate ...
Sanofi, the prominent pharmaceutical conglomerate, has undertaken a recent merge...
Surrozen finds itself at a crossroads in its pursuit of a treatment for inflamma...
AM-Pharma B.V. announced that the first individuals have been given treatment in...
Sun Pharmaceutical and Taro Pharmaceutical have formally announced their merger ...
Balversa (erdafitinib) has received complete approval from the FDA, permitting i...
